Meta-Analysis & Evidence Synthesis

Network Meta-Analysis Services

When more than two treatments or interventions compete and no single trial has compared them all, network meta-analysis brings the whole evidence base together—ranking options and estimating comparisons that were never tested head-to-head. We design and deliver network meta-analyses to current methodological standards.

Network meta-analysis (NMA) is a meta-analysis method that compares three or more treatments simultaneously by combining direct evidence (from head-to-head trials) with indirect evidence (through common comparators). It estimates all pairwise comparisons—even those never tested directly—and ranks the options, provided the network is connected and consistent.

Direct + indirect evidence PRISMA-NMA reporting Frequentist or Bayesian Reproducible, journal-ready
Sample treatment network A network diagram of five treatments connected by solid lines for direct comparisons and dashed lines for indirect comparisons. network_meta_analysis · evidence network A B C D E
Sample network direct indirect

What network meta-analysis does

A conventional (pairwise) meta-analysis answers one question at a time: does treatment A beat treatment B? But most real decisions involve a field of competing options—several drugs, several interventions, several policies—and the trials that exist rarely compare all of them against each other. Some pairs have been tested head-to-head; many have not. Network meta-analysis solves this by analysing the entire network of comparisons at once.

It works by combining two kinds of evidence. Direct evidence comes from trials that compared two treatments head-to-head. Indirect evidence is inferred through a common comparator: if A was compared with C, and B was compared with C, then A and B can be compared indirectly through C—even though no trial ever pitted A against B. NMA pools direct and indirect evidence coherently across the whole network, producing an estimate for every pairwise comparison and, often, a ranking of all the treatments.

When to use it

Network meta-analysis is the right tool when your review question involves three or more interventions and you need to compare them against one another—particularly when the direct, head-to-head evidence is incomplete. It is widely used in health technology assessment and clinical guideline development, and increasingly in management, education, and policy research wherever multiple interventions target the same outcome.

If your question is simply “does A work better than B,” a standard pairwise meta-analysis is sufficient; NMA earns its extra complexity only when several options must be compared and ranked together.

At a glance

Pairwise vs network meta-analysis

Pairwise meta-analysisNetwork meta-analysis
Treatments comparedTwoThree or more, simultaneously
Evidence usedDirect onlyDirect + indirect combined
AnswersDoes A beat B?How do all options compare and rank?
Key requirementComparable studiesConnected network + transitivity/consistency
Use whenOne comparison mattersMany options must be ranked
Methodology

The assumptions that make it valid

NMA is powerful, but its credibility rests on assumptions that must be checked rather than assumed. The central one is transitivity: the studies making up the different comparisons must be similar enough in their participants, settings, and design that indirect comparisons are meaningful—in effect, that the common comparator behaves the same way across the network. Its statistical counterpart is consistency: where direct and indirect evidence exist for the same comparison, they should broadly agree. Where they diverge (inconsistency), the network’s results cannot be taken at face value until the source is understood.

A network also has to be connected—every treatment must link to the others through some chain of comparisons—or the disconnected part cannot be included. And, as in any synthesis, heterogeneity across studies and publication bias remain live concerns. A rigorous NMA reports the network geometry, tests transitivity and consistency explicitly, and is honest about where the evidence is thin.

Indirect evidence is only as good as the transitivity assumption. If the trials behind different comparisons differ systematically, indirect comparisons can mislead. Checking transitivity and consistency—not just running the model—is what separates a trustworthy network meta-analysis from a fragile one.

Ranking treatments—with caution

One of NMA’s most attractive outputs is a ranking of all the treatments, often summarised with statistics such as SUCRA. Rankings are useful but invite over-interpretation: a treatment can rank first while the evidence for it is sparse or uncertain, and small differences in rank are often not meaningful. We present rankings alongside the effect estimates and their uncertainty—never as a bare league table.

How we work

How we deliver a network meta-analysis

Network meta-analysis sits within our wider meta-analysis and evidence-synthesis service, run as part of a full systematic-review workflow—so the network is built on a sound review, not bolted onto a shaky one.

We begin with a registered protocol, a comprehensive and documented search, careful data extraction, and risk-of-bias assessment before any modelling. We then construct and visualise the network, choose an appropriate framework (frequentist or Bayesian) for the data and question, test transitivity and consistency, and fit the model.

Reporting follows the PRISMA extension for network meta-analyses, with methodological guidance drawn from established sources such as Cochrane.

You receive the network plot, a league table of all pairwise comparisons, ranking statistics, and a full assessment of heterogeneity and bias—all reported to PRISMA-NMA standards and delivered with reproducible code. The result is analysis you can defend in peer review, not a black-box output.

Where we apply it

Network meta-analysis across Management & Allied Studies

Network meta-analysis originated in health technology assessment and remains most established there, but it applies wherever several interventions, policies, or strategies compete to influence the same outcome and a connected network of comparisons exists. We confirm that requirement before recommending it.

Management & Organisational Studies

Comparing leadership, HR, and change-management interventions on performance, engagement, or turnover—where trials rarely test every approach head-to-head.

Economics & Public Policy

Ranking competing policy instruments or programme designs on economic and social outcomes by pooling direct and indirect evidence across evaluations.

Marketing & Consumer Research

Comparing promotional, pricing, or communication strategies on conversion, loyalty, and brand outcomes across many separate studies.

Finance & Accounting

Applicable where several interventions or regimes have been compared across studies with shared comparators—less common here, so we confirm the network is connected before recommending NMA.

Education & Learning Sciences

Ranking teaching methods, edtech tools, or interventions on learning outcomes when head-to-head comparisons are scarce.

Operations & Information Systems

Comparing process, technology-adoption, or system-design interventions on efficiency, quality, and adoption outcomes.

FAQ

Network meta-analysis: common questions

Network meta-analysis (NMA) compares three or more treatments simultaneously by combining direct evidence from head-to-head trials with indirect evidence through common comparators. It estimates every pairwise comparison—including ones never tested directly—and can rank the treatments, provided the network is connected and the transitivity and consistency assumptions hold.
A standard (pairwise) meta-analysis compares two treatments using direct evidence only. Network meta-analysis compares three or more at once, combining direct and indirect evidence across a network of studies, so it can estimate and rank comparisons that no single trial examined. It is more powerful but requires additional assumptions—transitivity and consistency—that must be tested.
Transitivity is the assumption that the studies forming different comparisons are similar enough—in participants, settings, and design—that indirect comparisons through a common comparator are valid. If the trials differ systematically, indirect evidence can mislead. Its statistical counterpart, consistency, checks that direct and indirect evidence agree where both exist. Both should be assessed, not assumed.
No. Ranking statistics such as SUCRA are useful but easily over-interpreted—a treatment can rank highly on sparse or uncertain evidence, and small rank differences are often not meaningful. Rankings should always be presented alongside the effect estimates, their uncertainty, and the strength of the underlying evidence, never as a bare league table.
Both are valid, and the choice depends on the data and the question. Bayesian network meta-analysis is common and handles ranking and uncertainty naturally; frequentist approaches are efficient and widely accepted. We select the framework that best fits your review, justify it transparently, and deliver reproducible code either way.

Comparing several treatments or interventions?

If your review question spans multiple options and the head-to-head evidence is incomplete, a network meta-analysis may be exactly what it needs. We scope, design, and deliver it to PRISMA-NMA standards.